Nascent Biotech
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$14.77K
-0.0
-0.02
Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of monoclonal antibodies for the treatment of various forms of cancer. The company is headquartered in North Palm Beach, Florida. The company went IPO on 2012-06-06. The firm focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The firm's lead candidate, Pritumumab (PTB), is a human monoclonal antibody (Mab) that has progressed to Phase 2 clinical trials for the treatment of Brain Cancer. Pritumumab is a fully natural human IgG antibody that was derived using proprietary technology from a B-cell isolated from a tumor draining lymph node of a patient with cervical cancer. Its other products include CLNH5 and MultiPharm. MultiPharm is a proprietary platform technology that may have additive and synergistic effects not only for cancer therapy but also for diabetes, autoimmunity, and transplantation.
emptyResult
Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of monoclonal antibodies for the treatment of various forms of cancer. The company is headquartered in North Palm Beach, Florida. The company went IPO on 2012-06-06. The firm focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The firm's lead candidate, Pritumumab (PTB), is a human monoclonal antibody (Mab) that has progressed to Phase 2 clinical trials for the treatment of Brain Cancer. Pritumumab is a fully natural human IgG antibody that was derived using proprietary technology from a B-cell isolated from a tumor draining lymph node of a patient with cervical cancer. Its other products include CLNH5 and MultiPharm. MultiPharm is a proprietary platform technology that may have additive and synergistic effects not only for cancer therapy but also for diabetes, autoimmunity, and transplantation.
Recently from Cashu
Nascent Biotech Explores Collaborations Amid Steel Industry Acquisition Dynamics
Nascent Biotech Eyes Strategic Collaborations Amid Steel Acquisition Moves In light of recent developments in the steel industry, Nascent Biotech finds itself at a pivotal point for potential partners…
Nascent Biotech Prioritizes Strategic Collaborations to Enhance R&D and Drive Innovation
Nascent Biotech's Strategic Focus on Collaboration in the Biotechnology Sector Nascent Biotech is poised to redefine its operational strategy by emphasizing strategic partnerships to enhance its resea…
Nascent Biotech: SGH Ltd's Strategic Acquisition of BlueScope Steel and Industry Implications
SGH Ltd's Strategic Move in Steel Acquisition: A New Chapter for Industry Dynamics SGH Ltd's recent submission of a Non-Binding Indicative Offer (NBIO) to acquire BlueScope Steel Ltd represents a sign…
Nascent Biotech Supports Kennedy's Vaccine Oversight Reform for Enhanced Public Health Transparency
Reforming Vaccine Oversight: A New Frontier in Public Health Policy Robert F. Kennedy Jr. initiates a campaign that seeks to reform the federal government's approach to vaccine oversight, bringing ren…